Gland Pharma receives USFDA approval for Brimonidine Tartrate Ophthalmic Solution, 0.025%

India, March 4 -- Gland Pharma has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application filed for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC).The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Lumify Ophthalmic Solution, 0.025%, of Bausch & Lomb Inc.This Product is indicated to relieve redness of the eye.

Published by HT Digital Content Services with permission from Pivotal Sources....